High Dose Ifosfamide in Combination with Etoposide and Epirubicin Followed by Autologous Stem Cell Transplantation in the Treatment of Relapsecd/Refractory Hodgkin's Disease: a Report on Toxicity and Efficacy On behalf of the Scotland and Newcastle Lymphoma Group

References

• Taylor P. R. A., Angus B., Owen J. P., Proctor S. J. Hodgkin's disease: a population‐adjusted clinical epidemiology study (PACE) of management at presentation. Quarterly Journal of Medicine 1998; 91: 131–139
   Google Scholar
• Bartlett N. L., Rosenberg S. A., Hoppe R. T., Hancock S. L., Homing S. J. Brief chemotherapy, Stanford V, and adjunct Radiotherapy for bulky advanced‐stage Hodgkin's Disease: A preliminary Report. Journal of Clinical Oncology 1995; 13: 1080–1088
   PubMed Web of Science ®Google Scholar
• Taylor P. R. A., Jackson G. H., Lennard A. L., Lucraft H., Proctor S. J., on behalf of the Newcastle and Northem Region Lymphoma Group. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non‐cryopreserved marrow rescue. British Journal of Cancer 1993; 67: 383–387
   PubMed Web of Science ®Google Scholar
• Longo D. L., Duffey P. L., Young R. C., Hubbard S. M., Ihde D. C., Glatstein E., Phares J. C., Jaffe E. S., Urba W. J., De Vita V. T., Jr. Conventional‐dose salvage combination chemotherapy on patients relapsing with Hodgkin's Disease after combination chemotherapy: the low probability for cure. Journal of Clinical Oncology 1992; 10(2)210–218
   PubMed Web of Science ®Google Scholar
• Case D. C., Anderson J., Ervin T. J., Gottlieb A. Phase II trial of ifosfamide and MESNA in previously treated patients with non‐Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552. Hematological Oncology 1991; 9: 189–196
   PubMed Web of Science ®Google Scholar
• Rodriguez M. A., Cabanillas F. F., Hagemeister F. B., McLaughlin P., Romaguera J. E., Swan F., Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Annals of Oncology 1995; 6(6)609–611
   PubMed Web of Science ®Google Scholar
• Engert A., Schnell R., Kupper F., Reiser M., Engelhard M., Wilhelm M., Lathan B., Bakes‐Engler S., Winterhalter B., Scheuten M. E., Dederichs B., Tesch H., Wonnann B., Diehl V. A phase‐II study with idarubicin ifosfamide and VP‐16 (IIVP‐16) in patients with refractory or relapsed aggressive and high grade non‐Hodgkin's lymphoma. Leukemia and Lymphoma 1997; 24: 513–522
   PubMed Web of Science ®Google Scholar
• Child J. A., Simmons A. V., Bamard D. L., Parapia L., Morgan M., Grace R. J., Fletcher J., Parker D., Norfolk D. R., Stone J., Stuart N. S. A., Tucker J., Dovey G. J., For the Yorkshire Regional Lymphoma and Central Lymphoma Groups. Twin‐track studies of ifosfamide and mitoxantrone (I‐M) in recurrent high grade non‐Hodgkin's lymphoma and Hodgkin's disease. Hematological Oncology 1991; 9: 235–244
   PubMed Web of Science ®Google Scholar
• Schellong G., Homig‐Franz I. Salvage therapy results in childhood Hodgkin's disease. Autologous Bone Marrow Transplantation for Hodgkin's Disease. Non‐Hodgkin's Lymphoma and Multiple Myeloma. 1993; 8–10
   Google Scholar
• Zinzani P. L., Barbieri E., Visani G., Gherlinzoni F., Perini F., Neri S., Bendandi M., Ammendolia I., Salvucci M., Babini L., Tura S. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high‐grade non‐Hodgkin's lymphoma and Hodgkin's disease. Haemaiologica 1994; 79: 508–512
   PubMed Web of Science ®Google Scholar
• Ferme C., Bastion Y., Lepage E., Berger F., Brice P., Morel P., Gabane J., Nedellec G., Reman O., Cheron N., et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Annals of Oncology 1995; 6: 543–549
   PubMed Web of Science ®Google Scholar
• Bonfante V., Viviani S., Santoro A., Devizzi L., Di Russo A., Zanini M., Soncini F., Soto Parra H., Valagussa P., Bonadonna G. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. British Journal of Haematology 1998; 103: 533–535
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO handbook for reporting results of cancer treatment. World Health Organisation, Geneve 1979
   Google Scholar
• Gribben J. G., Linch D. C., Singer C. R. J., McMillan A. K., Jarred M., Goldstone A. H. Successful treatment of refractory Hodgkin's disease by high‐dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73(1)340–344
   PubMed Web of Science ®Google Scholar
• Lister T. A., Crowther D., Sutcliffe S. B., Glatstein E., Canellos G. P., Young R. C., Rosenberg S. A., Coltman C. A., Tubiana M. Report of a Committee Convened to Discuss the Evaluation and Staging of Patients with Hodgkin's Disease: Cotswolds Meeting. Journal of Clinical Oncology 1989; 7(11)1630–1636
   PubMed Web of Science ®Google Scholar
• Majolino I., Scime R., Indovina A., Vasta S., Patti C., Gentile S., Santoro A., DiNoto R., Fabbiano F., Guamaccia C. Treatment of malignant lymphomas with very high dose CVB followed by transplantation of autologous blood stem cells collected after mobilizing chemotherapy. Haematologica 1991; 76: 66–71
   PubMedGoogle Scholar
• Santoro A., Bonadonna G. Prolonged disease‐free survival in MOPP‐resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemotherapy and Pharmacology 1979; 2: 101–105
   PubMed Web of Science ®Google Scholar
• Santoro A., Viviani S., Valagussa P., Bonfante V., Bonadonna G. CCNU, etoposide and prednisolone (CEP) in refractory Hodgkin's disease. Seminars in Oncology 1986; 13: 23–26
   PubMed Web of Science ®Google Scholar
• Lennard A., Proctor S. J., Dawson A., Prescott R., Lucraft H., Parker A., Leonard R. C. F., Ritchie G., Allan N. C., Scott S. Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin's disease. A prospective study on behalf of the ESNLG. Hematological Oncology 1989; 7: 77–86
   PubMed Web of Science ®Google Scholar
• Lennard A. L., Carey P. J., Jackson G. H., Proctor S. J. An effective oral combination in advanced relapsed Hodgkin's disease: Prednisolone, etoposide, chlorambucil and CCNU. Cancer Chemotherapy and Pharmacology 1990; 26: 301–305
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Valagussa P., Santoro A. Alternating non‐cross‐resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Annals of Internal Medicine 1986; 104: 739–746
   PubMed Web of Science ®Google Scholar
• Cullen M. H., Stuart N. S. A., Woodroffe C., Murphy A., Fletcher J., Blackledge G. R. P., Child J. A., Grieve R. J., Jones E. L. ChlVPP/PABLOE and radiotherapy in advanced Hodgkin's disease. Journal of Clinical Oncology 1994; 12: 719–787
   Web of Science ®Google Scholar
• Smith M. R., Khanuja P. S., Katib A., Bishop C. R., Andersen J., Hussein M. E., Karanes C. Continuous infusion ABDIC therapy for relapsed or refractory Hodgkin's disease. Cancer 1994; 73: 1264–1269
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M. G., Rueffer U., Lathan B., Schmitz N., Brosteanu O., Hasenclever D., Haas R., Kirchner H., Koch P., Kuse R. Dexa‐BEAM in patient with Hodgkin's disease refractory to multidrug chemotherapy regimens; a trial of the German Hodgkin's Disease Study Group. Journal of Clinical Oncology 1994; 12: 580–586
   PubMed Web of Science ®Google Scholar
• Carrion J. R., Garcia Arroyo F. R., Salinas P. Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma. American Journal of Clinical Oncology 1995; 18(1)44–46
   PubMed Web of Science ®Google Scholar
• Spinolo J. A., Jagannath S., Velasquez W., Spitzer G., Cabanillas F., Hagemeister F., Honvitz L. J., Dicke K. A. Cisplatin‐CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. Leukemia and Lymphoma 1993; 9(1–2)11–77
   Web of Science ®Google Scholar
• Colwill R., Crump M., Couture F., Danish R., Stewart A. K., Sutton D. M., Scott J. G., Sutcliffe S. B., Brandwein J. M., Keating A. Mini‐BEAM as salvage therapy for relapsed or refactory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. Journal of Clinical Oncology 1995; 13(2)396–402
   PubMed Web of Science ®Google Scholar
• Weaver C. H., Schwartzberg L., Li W., Hazelton B., West W. High‐dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. Bone Marrow Transplantation 1996; 17(5)715–721
   PubMed Web of Science ®Google Scholar
• Meanwell C. A., Blake A. E., Kelly K. A., Honigsberger L., Blackledge G. Prediction of ifosfamide/MESNA associated encephalopathy. Eur. J. Cancer Clin. Oncol 1986; 22: 815–819
   PubMedGoogle Scholar
• McQuaker I. G., Haynes A. P., Stainer C., Anderson S., Russell N. H. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate‐dose cyclophosphamide. British Journal of Haemtology 1997; 98: 228–233
   PubMed Web of Science ®Google Scholar